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The aim of the present study was to investigate the in vivo antiproliferative effect of interferon alpha (IFN-a) in patients with
metastatic renal cell carcinoma (mRCC). Core needle biopsies of metastatic and/or the primary kidney cancer were obtained before
interleukin-2 (IL-2)- and IFN-a-based immunotherapy in 34 patients and repeated after 5 weeks in 25 patients. Tumour proliferation
was assessed by use of the anti-Ki-67 antibody MIB-1 and evaluated in multiple, random systematic sampled fields of vision. Ki-67
labelling index (LI) at baseline was median 13.6% (range 1.2–85.0) and median 10.6% (range 1.3–48.6%) at week 5 with a median
overall decline of 15.2% (range  95 to þ258%) from baseline to week 5. There was no difference between responding and
nonresponding patients. Ki-67 LI at week 5 was significantly correlated to survival. Thus, median survival of patients with Ki-67 LI
p10.6% at week 5 was 25.1 months compared to 11.5 months for patients with Ki-67 LI 410.6% (P¼0.016). Baseline or change in
Ki-67 LI did not correlate to survival. These data suggest that IFN-a in vivo has only modest effect on tumour proliferation in patients
with mRCC. Tumour Ki-67 (MIB-1) reactivity after 1 month of immunotherapy appears to be a significant predictor of patient survival.
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Metastatic renal cell carcinoma (mRCC) is refractory to conven-
tional therapies including radiation, hormones and chemotherapy
(Motzer and Russo, 2000). Patients with untreated mRCC have a
poor prognosis with a median survival of only 8 months (Haas
et al, 1993). However, interleukin-2 (IL-2)- and interferon-a (IFN-
a)-based immunotherapy can induce durable tumour regression in
5–10% of patients with mRCC (Minasian et al, 1993; Rosenberg,
2001).
Understanding of the mechanisms by which IL-2 and IFN-a
mediate their antineoplastic actions is incomplete. Whereas
cellular immune effector mechanisms are considered to be the
most important mediators of IL-2 antitumour activity (Rubin et al,
1989; Donskov et al, 2002a), IFN-a in addition (Kosmidis et al,
1992; Tsavaris et al, 1996; Donskov et al, 2002a) is considered to
exert antiproliferative (Grander et al, 1997) and differentiation-
inducing effects on the tumour cells (Pfeffer et al, 1998). In vitro,a
direct antiproliferative effect on renal tumour cells has been
demonstrated for IFN-a (Nanus et al, 1990), whereas IL-2 has no
direct impact on cancer cells (Rosenberg, 2001). However, despite
45 years since the discovery of IFN (Pfeffer et al, 1998), only one
study has evaluated the antiproliferative effect of IFN in vivo in
patients with mRCC (Yoshino et al, 2000). In that study, however,
only baseline tumours were analysed and no correlation to
objective response or survival was found (Yoshino et al, 2000).
A commonly used marker of tumour proliferation is Ki-67
(MIB-1), a monoclonal antibody recognising a nuclear protein
expressed in all active phases of the cell cycle (G1,S ,G 2 and M) but
absent in quiescent cells (G0) (Cattoretti et al, 1992). In
nephrectomy specimens of nonmetastatic RCC (Tannapfel et al,
1996; Aaltomaa et al, 1997; Kirkali et al, 2001; Rioux-Leclercq et al,
2001) and mRCC (Rioux-Leclercq et al, 2001), Ki-67 (MIB-1)
labelling index (LI) has been demonstrated as an independent
parameter of unfavourable prognosis.
To assess the in vivo antiproliferative properties of IFN-a during
treatment, we have monitored Ki-67 (MIB-1) LI in repeated core
needle tumour biopsies obtained at baseline and at week 5 of IL-2-
and IFN-a-based immunotherapy in patients with mRCC and
correlated the findings with objective response and survival.
MATERIALS AND METHODS
Patients and samples
A total of 49 consecutive single-institution patients with mRCC
were treated on an outpatient basis from February 1999 to August
2000 at the Department of Oncology, Aarhus University Hospital.
Of these, 26 were enrolled in a Scandinavian, multicentre
prospective phase II trial of s.c. IL-2, IFN-a and histamine
dihydrochloride (Donskov et al, 2002b). The treatment plan
consisted of one priming-week of daily IFN-a and up to nine
treatment cycles of 4 weeks with IFN-a (human leucocyte IFN-a,
Interferon Alfanative
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ldose, s.c. once daily, 7 days per week throughout the study), IL-2
(Aldesleukin, rIL-2, Proleukin
s, Chiron, The Netherlands, 2.4
MIUm
 2, s.c., two times daily 5 days per week, weeks 1 and 2 every
cycle) and histamine (Maxim Pharmaceuticals Inc., San Diego, CA,
USA, 1.0mg in 1.0ml by 20min slow s.c. injections, two times
daily, 5 days per week throughout the study).
The subsequent 23 patients were treated with the same schedule
as the phase II trial, but without histamine (Donskov et al,
submitted for publication). Moreover, instead of leucocyte IFN,
which was used because of the tradition in Sweden, recombinant
IFNa-2b (Introna
s, Schering-Plough, Denmark) was applied by
the same dose and schedule.
Histamine did not add efficacy with respect to response, time to
progression or survival, and did not influence levels of intratu-
moral or blood leucocyte numbers, zeta chain expression or
cytotoxicity (Donskov et al, 2003). Thus, the present study was
based on the pooled data from these two treatment groups.
Of the 49 patients, 45 gave written informed consent for
sequential core needle biopsies. Two patients did not complete one
course of therapy because of toxicity and were not evaluable for
objective response. These two patients were excluded from all
further analyses. Two patients were excluded from the present
study using core needle biopsies as they had only fine needle
biopsies performed. Three patients had no biopsies performed for
safety reasons because tumours were not accessible for core needle
biopsies (metastases located in lung, bone, mediastinal lymph
node or retrocrural lymph node close to aorta). No complete
responding patients had accessible tumours for core needle
biopsies. Thus, a total of 38 patients were included in the present
study with sequential core needle tumour biopsies. Core needle
biopsies (18G cutting needle) were collected by standard
ultrasound-guided procedures (Jennings et al, 1989) at baseline
and after 1 month of immunotherapy on day 1 in the fifth
treatment week. On-treatment biopsy was obtained from the same
tumour as baseline. A total of 76 core needle biopsies in 38 patients
were performed at different tumour sites (kidney, n¼43;
abdominal soft tissue, n¼10; liver, n¼8; pleura, n¼4; muscle,
n¼4; kidney bed, n¼3; subcutis, n¼2; and lymph node, n¼2).
There were four nonevaluable patients for the analyses, two
because of insufficient tumour tissue in the biopsies and two
because of necrosis in all biopsies at both biopsy time points. Eight
patients had only a baseline biopsy performed (withdrawal of
consent). Of the 76 biopsies, 13 (17%) were excluded because of
necrosis. Thus, at baseline and after 1 month of immunotherapy,
34 and 25 patients, respectively, had evaluable biopsies.
Patient characteristics for the 34 patients are given in Table 1.
Distribution of prognostic factors according to Memorial Sloan
Kettering Cancer Center (MSKCC) (Motzer et al, 1999) and UCLA
Integrated Staging System (Zisman et al, 2001) are given in Table
2a and b.
According to the Union Internationale Contre le Cancer (UICC)
and the American Joint Committee on Cancer (AJCC) 1997
classification (Reuter and Presti, 2000), all patients had conven-
tional (clear cell) RCC except two, who had papillary RCC and
collecting duct RCC. These two patients achieved stable disease
and progressive disease, respectively. All patients had stage IV
disease, according to the TNM classification (Guinan et al, 1997).
Immunohistochemistry
Sections (2mm) of formalin-fixed, paraffin-embedded biopsies
were mounted on ChemMate slides (cat. no. S2024 DAKO,
Table 1 Baseline patient characteristics (n¼34)
Median age, years (range) 56 19–74
Sex
Male 26 76%
Female 8 24%
Karnofsky performance status
100 11 32%
90 11 32%
80 6 18%
70 6 18%
Prior therapy
Nephrectomy 12 35%
Excision of metastatic lesions 6 18%
None 19 56%
Number of disease sites
11 3 %
2 10 29%
3 12 35%
4 or more 11 32%
Most common sites of disease
Primary kidney tumour 22 65%
Local recurrence kidney bed 7 21%
Lung/pleura 20 59%
Lung metastasis alone 0 0%
Lymph node 17 50%
Liver 10 29%
Bone 13 38%
Soft tissue 10 29%
Table 2 Distribution of prognostic factors
Consecutive patients Evaluable patients Baseline patients Week-5 patients
Prognostic group n¼49 % n¼46 % Pn ¼34 % Pn ¼25 % P
(a) MSKCC
a
Favourable 3 6% 3 7% 0.66 2 6% 0.70 2 8% 0.59
Intermediate 25 51% 24 52% 16 47% 14 56%
Poor 21 43% 19 41% 16 47% 9 36%
(b) UISS
b
Baseline patients Week-5 patients
n¼34 % n¼25 % P
UISS 3 6 18% 5 20% 1.00
UISS 4 27 79% 19 76%
UISS 5 1 3% 1 4%
P¼Fisher’s exact test.
aMotzer et al (1999). Risk factors: Karnofsky PS o80, LDH X1.5 times upper limit of normal, haemoglobin olower limit of normal, corrected s-Ca
410mgdl
 1 or ion-Ca 4upper limit of normal and no prior nephrectomy. No risk factors¼favourable prognosis, 1–2 risk factors¼intermediate prognosis and 42 risk
factors¼poor prognosis.
bUCLA Integrated Staging System (Zisman et al, 2001), based on TNM stage, Fuhrman grade and performance status.
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lDenmark), dried 1h at 601C, deparaffinised and rehydrated. After
endogenous peroxidase blocking (0.5% hydrogen peroxidase in
water for 30min), antigens were retrieved by microwave oven
heating (3 5min at 850W in Tris/EGTA retrieval buffer (pH
9.0)). The tissue sections were incubated for 1h with the Ki-67
(MIB-1) antibody diluted 1:100 (cat. no. IM 0505 Immunotech).
As second layer, EnVision (cat. no. K4000, DAKO) was used for
30min of incubation. Staining was visualised with diaminobenzi-
dine tetrahydrochloride solution, counterstained in Mayer’s
haematoxylin and mounted with Aqutex (64912-50, KEBO-lab,
Denmark). All staining was performed in a TechMate automate
machine (DAKO). As positive controls, a normal lymph node and
several non-mRCC tumours were used. As negative controls,
substitution of primary antibody with PBS and isotype IgG1 (cat.
no. 33811A, Pharmingen, Denmark) 1:50 was used.
Immunohistochemical evaluation
Stereologic counting of Ki-67 was performed using a light
microscope equipped with a CAST-grid software package (version
2.0, Olympus, Denmark) for manual interactive counting on a
computer screen, as previously described in detail (Gundersen
et al, 1988; Jensen et al, 1998). In brief, the stereologic estimates
were based on random and systematic sampling of counting fields
(4989mm
2 each) in the tumour tissue. A motorised stage,
controlled by the computer, made it possible to sample the first
counting field at random and then to move systematically
throughout the tumour section. Using a  40 objective, a median
number of 30 fields (range 12–30) and a median number of 444
tumour cells (range 49–949) were counted. The entire core needle
biopsy was assessed. Areas of necrosis were avoided. Tumour cells
were considered positive for Ki-67, if there was any staining of the
nucleoplasm or nucleoli, regardless of staining intensity. Prolifer-
ating tumour cells were distinguished from proliferating intratu-
moral immune cells on the basis of morphology and size. In case of
doubt, support from CD3 immunostaining (Donskov et al, 2002a)
was obtained. The labelling index of Ki-67 (Ki-67 LI) was defined
as the percentage of Ki-67-labelled tumour cells to the total
number of tumour cells counted. Staining was analysed blinded by
one observer (FD). For testing the reproducibility, sections were
ranked according to their number of proliferative cells and every
sixth case was selected and counted blinded by a senior
histopathologist (NM). A high level of reproducibility (Spearman’s
r¼0.90, P¼0.0001) was found.
Statistics
Overall survival was measured from first day of treatment until
death or last follow-up evaluation. The relationship between
assessed parameters and objective response was evaluated using
the nonparametric Mann–Whitney U test. The significance of
changes from baseline to week 5 was assessed using the Wilcoxon’s
signed rank test for paired samples. The relationship between
assessed parameters and survival was evaluated using the method
of Kaplan–Meier and the log-rank test. Dichotomy of the patients
was carried out at the median value for the evaluated parameter.
All tests were two-sided and the significance level was 0.05. The
median follow-up period was 44.7 months (range 33.3–50.4
months). Data were updated in June 2003. Statistical analyses
were performed using SPSS v10.0.
RESULTS
Clinical treatment results
A total of 34 patients treated with low dose IL-2, IFN-a with or
without histamine were evaluable for consecutive tumour biopsies.
Of these, six patients achieved partial remission (PR), 11 patients
achieved stable disease (SD) and 17 patients had progressive
disease (PD). Median survival was 13.3 months (range 1.3–50.4þ
months). Four patients (three with PR and one with SD) had no
evidence of disease (NED) and were alive at 33þ,4 0þ,4 7þ and
50þ months, respectively, after immunotherapy followed by
subsequent resection of residual tumour. At the time of analysis,
28 patients had died, giving a censoring rate of 17.7%.
Correlation between tumour nuclear Ki-67 (MIB-1)
staining and objective response
Baseline and on-treatment tumour proliferation defined by Ki-67
immunohistochemistry staining were evaluated and correlated to
objective response. The Ki-67 (MIB-1) LI was median 13.6% (range
1.2–85.0%) at baseline and median 10.6% (range 1.3–48.6%) after
1 month of therapy (Figure 1). When Ki-67 LI of responding (PR)
and nonresponding patients (SD, PD) at baseline and after 1
month of therapy was compared, no significant differences were
noted (P¼0.7 and 0.4, respectively). Also when Ki-67 LI of PD
patients and non-PD patients (PR, SD) at baseline and after 1
month of therapy was compared, no significant differences were
noted (P¼0.7 and 0.3, respectively). However, patients who
obtained no evidence of disease (NED, n¼4) had significantly
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Figure 1 Tumour cell proliferation marker Ki-67 (MIB-1) LI in patients
with mRCC (A) before and (B) after 1 month of interleukin-2- and
interferon-a-based immunotherapy for patients obtaining partial response
(PR), stable disease (SD) and progressive disease (PD). The box plots
represent the median, the 25th and the 75th percentiles, respectively. The
error bars represent the 10th and the 90th percentiles, respectively.
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llower Ki-67 LI (P¼0.022) than non-NED patients (n¼21) at week
5, whereas no difference was found (P¼0.4) at baseline.
A median overall decline of 15.2% (range –95 to þ258%) in Ki-
67 tumour expression from baseline to week 5 was observed
(P¼0.39) (Figure 2). When correlated to objective response, no
significant difference (P¼0.8) was found.
Correlation between tumour nuclear Ki-67 (MIB-1)
staining and survival
We also studied the influence of tumour proliferation on survival.
Ki-67 (MIB-1) LI at week 5 was statistically significantly associated
to survival (Figure 3). Median survival of patients with tumour cell
proliferation p10.6% at week 5 was 25.1 months compared to 11.5
months for patients with tumour cell proliferation 410.6%
(P¼0.016). Baseline or change in Ki-67 (MIB-1) LI was not
correlated to survival (P¼0.25 and 0.65, respectively).
DISCUSSION
This is to our knowledge the first in vivo serial assessment of the
antiproliferative properties of IFN-a during immunotherapy in
patients with mRCC. We observed only modest reduction in the
number of proliferating tumour cells induced by IFN-a- and IL-2-
based immunotherapy. Tumour Ki-67 (MIB-1) expression after 1
month of immunotherapy appeared to be a predictive marker of
survival, whereas at baseline, this marker failed as a marker of
unfavourable prognosis. The implication is that the proliferative
activity assessed after 1 month of immunotherapy has a greater
value as prognostic factor of survival as compared with baseline
assessment. One possible explanation might be that whereas the
majority of destruction of sensitive tumour targets appear within
the first courses of immunotherapy (Lindsey et al, 2000), resulting
in immunological ‘shaping’ or ‘sculpting’ of the tumours (Khong
and Restifo, 2002), the tumour after 1 month of immunotherapy is
less sensitive to immunotherapy and, thus, assessment of tumour
proliferation at this time has a greater value as a prognostic factor
for survival.
The general concept that aggressive tumours with elevated
baseline proliferative activity have a poor outcome in spite of the
treatment administered is not supported by our findings. We also
failed to demonstrate that long-term surviving patients after
immunotherapy treatment only had tumours with low baseline
proliferative activity, as has been reported in metastatic melanoma
(Vlaykova et al, 1999). In other words, the fate of a patient with
mRCC prior to IL-2- and IFN-a-based immunotherapy cannot be
determined by measuring baseline Ki-67 (MIB-1) LI.
Only 25 of 49 (51%) treated patients had evaluable biopsies after
1 month of treatment. Therefore, to make meaningful compar-
isons, a larger number of subjects are required. However, it should
be noted that patients at week 5 were randomly selected from, or
were at least representative of, a larger population, based on well-
known prognostic factors of MSKCC (Motzer et al, 1999) and UISS
(Zisman et al, 2001) (Table 2a and b).
In vitro, a direct antiproliferative effect on renal tumour cells has
been demonstrated for IFN-a (Nanus et al, 1990). IL-2 has no
direct impact on cancer cells, which can grow unimpeded in vitro
in high concentrations of IL-2 (Rosenberg, 2001). In vitro,
histamine inhibits oxygen radical formation in monocytes and
thus reverses oxidative inhibition of T cells and NK cells
(Hellstrand, 2002). No direct proliferative effect on renal tumour
0
10
20
30
40
50
60
70
80
90
Baseline Week 5
PR
Baseline Week 5
SD
Baseline Week 5
PD
K
i
-
6
7
 
(
M
I
B
-
1
)
 
L
I
K
i
-
6
7
 
(
M
I
B
-
1
)
 
L
I
0
10
20
30
40
50
60
70
80
90
K
i
-
6
7
 
(
M
I
B
-
1
)
 
L
I
0
10
20
30
40
50
60
70
80
90
Figure 2 Change in Ki-67 (MIB-1) LI in per cent at baseline and after 1
month of interleukin-2- and interferon-a-based immunotherapy for patients
obtaining partial response (PR), stable disease (SD) and progressive disease
(PD). The data points represent the Ki-67 (MIB-1) scores for individual
patients, a total of 34 patients at baseline and 25 patients after 1 month of
immunotherapy.
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Figure 3 Kaplan–Meier survival estimate demonstrating Ki-67 (MIB-1) LI
in tumour after 1 month of interleukin-2- and interferon-a- based
immunotherapy as a negative prognostic factor for survival in patients
with mRCC. Tick marks represent six censored patients.
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lcells has been demonstrated for histamine in vitro. However, by in
vivo administration of histamine to nonrenal tumour-bearing
rodents, both enhancement and suppression of tumour growth
have been reported (Hellstrand et al, 2000). This discrepancy may
be related to differential effects on the immune system rather than
proliferative effects on the tumour cells (Hellstrand et al, 1990).
Thus, despite patients in the present study received combination
immunotherapy and not single-agent IFN-a, it seems reasonable to
conclude that the observed antiproliferative effects are caused by
IFN-a.
We demonstrated only modest reduction in the number of
proliferating tumour cells induced by IFN-a. This finding is in
accordance with the results of two recent randomised phase III
trials in mRCC demonstrating a significant but only modest effect
of IFN-a (Medical Research Council Renal Cancer Collaborators,
1999; Pyrhonen et al, 1999). Thus, a British study with a total of
335 patients randomised to subcutaneous IFN-a or oral medrox-
yprogesterone acetate (MPA) (Medical Research Council Renal
Cancer Collaborators, 1999) demonstrated a significant absolute
improvement in 1-year survival of 12% (43 vs 31%) and a
significant improvement in median survival of 2.5 months (8.5 vs
6.0 months) for IFN-a-treated patients compared to MPA-treated
patients. Likewise, a Finnish study with a total of 160 patients
randomised to IFN-a plus vinblastine or vinblastine alone
(Pyrhonen et al, 1999) demonstrated a significant absolute
improvement in 1-year survival of 18% (56 vs 38%) and a
significantly prolonged median survival of 7.4 months (67.6 vs 37.8
weeks) for patients receiving both drugs. So although IFN-a has
reproducible antitumour effects in mRCC, these data demonstrate
the modest effect in mRCC and emphasise that novel treatment
strategies and identification of new agents with better antitumour
activity remain a high priority.
Despite 45 years since the discovery of IFN (Pfeffer et al, 1998)
and two decades since the first IFN treatment experience in mRCC
(Quesada et al, 1983), the exact mechanisms underlying the
antitumour response are not fully understood (Belardelli et al,
2002). Our tumour tissue analyses demonstrated only modest
reduction in the number of proliferating tumour cells induced by
IFN-a and IL-2, suggesting that immunotherapy reduces tumour
size but has only limited effect on intrinsic tumour aggressiveness
in vivo. We have previously demonstrated that localisation of
CD4
þ, CD8
þ and CD57
þ lymphocytes to sites of tumour is a
requisite for the response to therapy (Donskov et al, 2002a), thus
hypothesising that the antitumour activity of IFN-a in vivo is
primarily cellular immune mediated. This hypothesis is in
accordance with previous in vitro findings (Kosmidis et al, 1992;
Tsavaris et al, 1996).
In summary, the present study has assessed the Ki-67 (MIB-1)
tumour proliferation marker in mRCC at baseline and during IL-2-
and IFN-a based immunotherapy. Our data suggest that IFN-a in
vivo has only modest effect on tumour proliferation in patients
with mRCC. Tumour Ki-67 (MIB-1) reactivity after 1 month of
immunotherapy appears to be a significant predictor of patient
survival.
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